EPCAM and adenocarcinoma: To date, numerous preclinical studies have evaluated CAR-modified γδ T cells targeting neuroblastoma [152, 153], melanoma [154], B cell malignancies [153, 155], and epithelial cell adhesion molecule (epCAM)-positive adenocarcinomas [156].